The standstill agreement effectively neutralizes Psyence Labs as an activist threat for the duration of the restricted period. Monitor whether the issuer exercises its option to invest US$5,000,000 in Psyence Labs, as referenced in the standstill carve-out, which could signal deepening strategic ties rather than confrontation.
Price Chart
Executive Summary
Psyence Labs Ltd. filed Amendment No. 1 to its Schedule 13D, reporting the acquisition of 1,497,500 common shares of Psyence Biomedical Ltd. on October 1, 2026, via a share-for-share swap agreement. This increased its beneficial ownership to 2,643,659 shares, representing approximately 49.75% of the outstanding common shares. The filing also details a standstill agreement that significantly restricts Psyence Labs from taking activist actions, including acquiring additional shares, soliciting proxies, or seeking board representation without issuer consent.
Key Financial Metrics
Key Facts
- Psyence Labs acquired 1,497,500 common shares on October 1, 2026, via a share-for-share swap agreement with the issuer and a subsidiary.
- The swap involved the issuer issuing shares at a deemed price of US$6.00 per share for aggregate non-cash consideration of US$8,985,000.
- Following the acquisition, Psyence Labs beneficially owns 2,643,659 common shares, representing approximately 49.75% of the outstanding shares.
- The swap agreement includes broad standstill restrictions prohibiting Psyence Labs from acquiring additional shares, soliciting proxies, seeking board representation, or initiating extraordinary transactions without issuer consent.
- The filing amends the original Schedule 13D filed on June 3, 2026.
Financial Impact
Psyence Labs increased its stake to 49.75% via a non-cash share swap valued at US$8,985,000. The standstill agreement caps further activist escalation.
Risk Factors
- The standstill restrictions limit Psyence Labs' ability to push for changes, reducing near-term activist pressure.
- The 49.75% stake gives Psyence Labs significant influence but also subjects it to affiliate/control person resale restrictions.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13D/A Filing (Primary) | 0001213900-26-109613 |
| Document: 0001213900-26-109613-index-headers.html | 0001213900-26-109613 |
| Document: 0001213900-26-109613-index.html | 0001213900-26-109613 |
| Document: 0001213900-26-109613.txt | 0001213900-26-109613 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $4.52 $4.12 | ▼ −8.85% | ▼ −7.67% | $3.66 (−19.03%) |
Oct 15, 2026 11d ago | SC 13D/A | $4.32 $4.22 | ▼ −2.31% | ▼ −1.21% | $3.66 (−15.28%) |
Oct 5, 2026 21d ago | SC 13G | $5.08 $5.02 | ▼ −1.18% | ▼ −1.73% | $3.66 (−27.95%) |
Oct 5, 2026 21d ago | 6-K | $5.08 $5.02 | ▼ −1.18% | ▼ −1.73% | $3.66 (−27.95%) |
Oct 5, 2026 21d ago | Press Release | $5.08 $5.02 | ▼ −1.18% | ▼ −1.73% | $3.66 (−27.95%) |
Sep 28, 2026 28d ago | 6-K | $5.67 $5.43 | ▼ −4.15% | ▼ −3.96% | $3.66 (−35.39%) |
Sep 28, 2026 28d ago | Press Release | $5.67 $5.43 | ▼ −4.15% | ▼ −3.96% | $3.66 (−35.39%) |
Sep 23, 2026 4w ago | 6-K | $6.31 $5.86 | ▲ +7.13% | ▲ +7.05% | $3.66 (+42.00%) |
Sep 14, 2026 6w ago | 6-K | $6.00 $6.07 | ▲ +1.17% | ▲ +1.63% | $3.66 (−39.00%) |
Sep 2, 2026 7w ago | EFFECT | $4.37 $4.43 | ▲ +1.37% | ▲ +0.33% | $3.66 (−16.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers